Printer Friendly

PFIZER ANNOUNCES CALIFORNIA SUPREME COURT REVERSAL OF APPELLATE COURT DECISION IN HEART VALVE CASES

 NEW YORK, March 12 /PRNewswire/ -- Pfizer Inc (NYSE: PFE) announced today that the California Supreme Court yesterday granted the company's petition seeking relief from a Court of Appeal decision. The Court of Appeal will now review the Superior Court decisions in the Alsup and Moore cases.
 In those decisions, the Superior Court permitted non-California U.S. residents with working Shiley C/C heart valves to litigate in California. The state Supreme Court vacated the Court of Appeal decision not to hear the cases and directed the Court of Appeal to review the Superior Court's decision. These cases involve 16 out-of- state plaintiffs with working C/C heart valves that were manufactured by Shiley Incorporated, a Pfizer subsidiary.
 Pfizer General Counsel Paul S. Miller said: "We are pleased with this decision. In accordance with the California Supreme Court's earlier decision in the Stangvik case, we argued that cases brought by non-California residents should not be litigated in California. We will now go forward and argue the Alsup and Moore cases in the Court of Appeal."
 In November 1991, the California Supreme Court held in the Stangvik case that non-U.S. residents could not pursue heart valve fracture claims in California courts. In November 1992, however, the California Superior Court decided in the Alsup and Moore cases to allow non- California U.S. residents with working heart valves to pursue their claims in California.
 On Dec. 30, the Court of Appeal denied without explanation Pfizer's petition for a writ of mandate seeking review of the Superior Court decision. Pfizer then petitioned the California Supreme Court on the ground that the Superior Court's decision in the Alsup and Moore cases was contrary to the principles of the Supreme Court's holding in Stangvik, resulting in yesterday's decision. In the companion Retzlaff case, the Superior court ruled, consistent with the Supreme Court's decision in Stangvik, that claims filed by foreign residents with properly functioning Shiley C/C heart valves should be litigated in their home countries. Plaintiffs have appealed that decision to the Court of Appeal.
 -0- 3/12/93
 /CONTACT: A. A. Biesada, 212-573-2055, or Rick Honey, 212-573-2051, both of Pfizer/
 (PFE)


CO: Pfizer Inc; Shiley Incorporated ST: California, New York IN: MTC SU:

GK -- NY011 -- 5429 03/12/93 10:02 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 12, 1993
Words:379
Previous Article:ISDA BOARD MEMBERS AND CHAIRMAN ELECTED BAUMAN TO SUCCEED BASING AS CHAIRMAN
Next Article:DION ENTERTAINMENT TEAMS UP WITH MAJOR U.S. CASINO OPERATOR
Topics:


Related Articles
PFIZER REACHES AGREEMENT FOR SETTLING SHILEY C/C HEART VALVE CLAIMS; AGREEMENT IS SUBJECT TO APPROVAL BY COURT
FIRM REPRESENTING HEART VALVE RECIPIENTS OPPOSES SETTLEMENT PROPOSED BY PFIZER, INC.
PFIZER RELEASES STATEMENT ON CALIFORNIA COURT OF APPEAL DECISION
COURT APPROVES CLASS ACTION SETTLEMENT FOR PEOPLE WITH BJORK-SHILEY C/C HEART VALVES
PFIZER ANNOUNCES SETTLEMENT OF HEART VALVE LITIGATION
PFIZER RESPONSE TO CALIFORNIA SUPERIOR COURT DECISION
PFIZER RESPONDS TO CALIFORNIA COURT OF APPEAL DECISION
PFIZER SETTLES CALIFORNIA HEART VALVE CASES
PFIZER SUCCESSFUL IN APPEALS FROM BOWLING CLASS-ACTION DECISION
PFIZER ANNOUNCES THAT SUPREME COURT DECLINES SHILEY HEART VALVE REVIEW

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters